Valiant Organics Ltd

- There is no specific mention of any current or future fundraising through debt or equity in the provided transcript. - The company has been focusing on capex projects funded internally, with an annual capex range of INR 80 to 100 crores. - The management discussed ongoing capex for pharma intermediates (INR 60 crores) and OAP (INR 15 crores) but did not indicate raising funds through equity or debt. - They mentioned managing working capital and improving cash flows post-Sarigam incident, with some reduction in short-term borrowing. - No explicit plans for raising debt or equity were stated during the Q&A or management comments.

- Ongoing capex includes INR 15 crores for OAP (Ortho Anisic Phenol) and INR 60 crores for pharma intermediates, totaling around INR 75 crores. - Pharma intermediates capex is completed with trial runs done and awaiting government approvals (expected by end Q3 FY '23). - OAP capex is still ongoing with trial runs and some additional capex expected. - After commissioning these projects, further capex plans are unclear; typically, the company does INR 80-100 crores of annual capex. - The company is also analyzing new product opportunities, potentially involving a modest capex of around INR 40-45 crores if successful. - Focus remains on stabilizing current projects before launching new large investments. - The pharma intermediates plant will be captive to Aarti Pharmalabs. - Continuous development and trials ongoing to shift PAP production from batch to continuous process for efficiency gains.

- The company expects revenue growth of 5% to 10% for the current financial year (FY23), targeting INR 1,000 to 1,100 crores on a standalone basis. - For FY24 and beyond, a growth of around 30% is anticipated with full ramp-up of PAP (para Aminophenol), OAP (other agrochemicals project), and pharma intermediates. - Pharma intermediates plant expected to reach around 45-50% utilization in initial quarters of FY24 and full utilization by end of FY24, targeting about INR 50 crores revenue at full capacity. - Continuous process for PAP expected to increase production capacity from 500 to 1,000 metric tons per month once technical challenges are resolved, likely in upcoming financial years. - Volume recovery at Sarigam plant to full original levels (~4,000-4,500 tons per quarter) by Q4 FY23. - Overall growth driven by stabilizing raw material prices, operational improvements, and new product launches.

- The company expects a turnover of around INR 60 crores from the pharma intermediates product, with an asset turnover of approximately 1x, potentially a little more. - Margins for pharma intermediates are expected to be aligned with company-level margins; specific product margins are not disclosed. - Revenues were impacted by the Sarigam incident, causing a top-line loss of around 15-20% quarterly; full production recovery is expected by March, with growth of 5-10% by year-end on a standalone basis. - For FY '23, an average EBITDA margin of around 17% is anticipated, improving from earlier quarters due to stabilized raw material costs; margins of 17-18% projected full-year. - Post stabilization, the company targets 30% growth in the following year, driven by full utilization of PAP, along with OAP and pharma intermediates ramp-up. - Annual capex is targeted around INR 80-100 crores to support growth. - Long-term ROC improvements are expected but uncertain if pre-challenge historic levels (40%-60%) will be reached soon.

- The Sarigam plant had an incident impacting production and order fulfillment, causing a phased restart and lag in order execution. - The management mentioned a lag in fulfilling certain orders due to the Sarigam plant being non-operational and phased ramp-up post-incident. - Global demand issues, especially in Europe due to geopolitical and energy crisis, have also affected export order volumes. - The company expects a recovery in production and order execution once the Sarigam plant stabilizes and global demand improves. - New product development and capex for pharma intermediates and OAP are underway, with expectations to increase revenues and order inflow upon commissioning. - No specific quantitative orderbook or pending order values were disclosed in the transcript.